Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
02 November 2021 - 11:00PM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage
biopharmaceutical company focused on the development of novel
targeted therapeutics for Alzheimer’s disease (AD), today announced
the company will deliver an oral presentation on the clinical trial
framework of its product candidate, ACU193, at the 2021 Clinical
Trials on Alzheimer’s Disease (CTAD) conference, being held
in-person and virtually November 9-12 in Boston. ACU193 is a
monoclonal antibody that selectively targets toxic soluble
amyloid-beta oligomers (AβOs) for the treatment of early
Alzheimer’s disease.
Toxic soluble AβOs have been found to interact
within synapses of brain cells called neurons, which leads to
altered neuronal function, and may initiate and perpetuate the
process of neurodegeneration, ultimately leading to cell death.
“We believe research over more than two decades
has pointed toward toxic soluble Aβ oligomers as a promising
therapeutic target for Alzheimer’s disease,” said Eric Siemers,
M.D., Chief Medical Officer at Acumen. “ACU193 is differentiated in
its selective targeting of Aβ oligomers, providing the possibility
of short-term improvements in synaptic function in addition to
potential long-term disease modification with slowing of the
Alzheimer’s disease process. We believe that oligomer-specific
therapeutics are less likely to result in amyloid-related imaging
abnormalities – or ARIA – a major safety concern for
plaque-targeting drugs.”
Dr. Siemers’ presentation at CTAD will discuss
the scientific rationale for targeting AβOs, the clinical trial
design of the Phase 1 INTERCEPT-AD study of ACU193, and how the
study is designed to measure potential improvements in cognition
and blood flow in the brain.
Details of the oral presentation:
- Presentation number: OC3
- Presentation Title: Phase 1 trial design for
ACU193, a monoclonal antibody that selectively binds soluble Aβ
oligomers
- Presenter: Eric Siemers, M.D., Chief Medical
Officer, Acumen Pharmaceuticals
- Date & Time: Wednesday, Nov. 10, 2021;
9:20 a.m. ET
- Location: Boston Park Plaza, Grand Ballroom
A
The presentation will be streamed live on the
CTAD digital platform and a recorded version of the presentation
will be available within 48 hours after the event on the CTAD
website for those registered for the meeting.
About ACU193ACU193 is a
monoclonal antibody (mAb) discovered and developed based on its
selectivity for soluble AβOs, which Acumen believes are the most
toxic and pathogenic form of Aβ relative to Aβ monomers and amyloid
plaques. Soluble AβOs have been observed to be potent neurotoxins
that bind to neurons, inhibit synaptic function and induce
neurodegeneration. By selectively targeting toxic soluble AβOs,
ACU193 aims to directly address what a growing body of evidence
indicates is a primary underlying cause of the neurodegenerative
process in AD.
About INTERCEPT-AD
Approximately 62 individuals with early AD (mild cognitive
impairment or mild dementia due to AD) are expected to be
randomized into this double-blind, placebo-controlled,
first-in-human study of ACU193. INTERCEPT-AD is designed to
establish safety and proof of mechanism. It consists of
single-ascending-dose (SAD) and multiple-ascending-dose (MAD)
cohorts and is designed to evaluate the safety, tolerability,
pharmacokinetics (PK), and target engagement of intravenous doses
of ACU193. The study is enrolling at multiple investigative sites
located in the United States. More information can be found on
www.clinicaltrials.gov, NCT identifier NCT04931459.
About Acumen Pharmaceuticals,
Inc.Acumen Pharmaceuticals, headquartered in
Charlottesville, Va. with clinical operations based in Carmel,
Ind., is a clinical stage biopharmaceutical company developing a
novel disease-modifying approach to treat Alzheimer’s disease.
Acumen’s scientific founders pioneered research on toxic soluble
AβOs, which a growing body of evidence indicates are primary
triggers of Alzheimer’s disease pathology. Acumen is currently
focused on advancing its investigational product candidate, ACU193,
a humanized monoclonal antibody that selectively targets toxic
soluble AβOs in a Phase 1 clinical trial involving early
Alzheimer’s disease patients. For more information, visit
www.acumenpharm.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Any statement describing Acumen’s goals, expectations, financial or
other projections, intentions or beliefs is a forward-looking
statement and should be considered an at-risk statement. Words
such as “believes,” “expects,” “anticipates,” “could,” “would,”
“seeks,” “aims,” “plans,” “potential”, “will” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Forward-looking statements include statements
concerning Acumen’s business and the therapeutic potential of
Acumen’s product candidate, ACU193, including its potential for
improved safety and efficacy as compared to other monoclonal
antibodies in development, as well as the expectations concerning
the INTERCEPT-AD trial. These statements are based upon the current
beliefs and expectations of Acumen management, and are subject to
certain factors, risks and uncertainties, particularly those
inherent in the process of discovering, developing and
commercializing safe and effective human therapeutics. Such risks
may be amplified by the impacts of the COVID-19 pandemic. These and
other risks concerning Acumen’s programs are described in
additional detail in Acumen’s filings with the Securities and
Exchange Commission (“SEC”), including in Acumen’s Quarterly Report
on Form 10-Q for the quarter ended June 30, 2021, filed with the
SEC on August 16, 2021, which is available on the SEC’s website at
www.sec.gov. Copies of these and other documents are available from
Acumen. Additional information will be made available in other
filings that Acumen makes from time to time with the SEC. These
forward-looking statements speak only as of the date hereof, and
Acumen expressly disclaims any obligation to update or revise any
forward-looking statement, except as otherwise required by law,
whether, as a result of new information, future events or
otherwise.
Contacts:
Media:AcumenPR@westwicke.com
Investors:investors@acumenpharm.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Apr 2023 to Apr 2024